Shi JH, et al. - Since human epidermal growth factor receptor 2 (HER2) may be a new target as a treatment option for hepatocellular carcinoma (HCC) as well as tumor recurrence after surgery, researchers focused on the status of HER2 expression in HCC as well as its association with postoperative tumor recurrence. Using TCGA HCC cohort, GSE89377 and GSE115018, they extracted clinical and mRNA data of HCC patients. They determined the expression of HER2, E-cadherin, and Vimentin using Western Blotting and immunohistochemistry. Assessment of HCC biology (including cell survival, proliferation, and epithelial-to-mesenchymal transition phenotypes) was done in HepG2, JM1, HER2-transfected McA cells, and transforming growth factor beta (TGF-β) cocultured JM1 cells. HCC datasets revealed ERBB2 mRNA amplification as well as downregulation of its expression in high grade HCC with a worse overall survival. Findings revealed an association of HER2 expression pattern with tumor stage and overall survival; the transforming function of HER2 was found more relevant through β-catenin and SMAD3. In order to suppress the HER2-mediated tumor growth during postoperative liver regeneration, HER2-targeted treatment was advised.